Rafael Holdings, Inc.
RFL · XNYSCIK 1713863fmd_1BMNDMB66GPE8KB80G5JWQQ2BRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Aug 01, 2015 to Jul 31, 2026, 40 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Rental revenue | 1 | 1 | 1 | 2 | 0 | 0 | – | – | – | – |
| Total revenues | 6 | 4 | 5 | 5 | 1 | 0 | 0 | 1 | 1 | 1 |
| Net interest income | 0 | 0 | 0 | (0) | (0) | – | – | – | – | – |
| Cost of revenue | – | – | – | – | 3 | 3 | – | 0 | – | – |
| Realized investment gains (losses) | – | 0 | 0 | – | – | – | 0 | (0) | – | – |
| Gross profit | – | – | – | – | (2) | (3) | – | 0 | – | – |
| Research and development | – | 1 | 1 | 2 | 5 | 9 | 6 | 4 | 13 | 24 |
| Selling, general and administrative | 4 | 6 | 9 | 9 | 17 | 17 | – | – | – | – |
| Gain on sale of real estate | – | – | – | – | 1 | – | 1 | – | – | – |
| Compensation and benefits | 1 | – | – | – | – | – | – | – | – | – |
| Operating income | 0 | (4) | (7) | (8) | (28) | (60) | (15) | (103) | (29) | (33) |
| Interest expense | – | – | 0 | 0 | 0 | 0 | – | 0 | 1 | 0 |
| Other non-operating income (expense) | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Income before taxes | 0 | (4) | (5) | (7) | (23) | (140) | (9) | (67) | (33) | (28) |
| Income tax expense | 0 | 8 | (0) | 0 | 0 | – | (0) | (3) | (3) | (0) |
| Net income from continuing operations | 0 | (12) | (5) | (7) | (23) | (141) | (9) | (65) | (31) | (28) |
| Net income | 0 | (12) | (5) | (11) | (23) | (125) | (2) | (34) | (31) | (30) |
| Net income to common shareholders | – | – | – | – | (25) | (125) | (2) | (34) | – | – |